Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-09-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 15.9% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: melanomaskinimmunotherapymgother protocol
  Phrases that lowered it: and safetyefficacy andthe efficacysafety ofpatients who
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 29.5% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 1292 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Keywords listed: 21 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 97.2% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports before start: 2499 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. NCT01777776 · started 2013 · scored riskier than 61% of active trials terminated
• A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma NCT01436656 · started 2011 · scored riskier than 97% of active trials completed
• A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma NCT01320085 · started 2011 · scored riskier than 99% of active trials completed
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma NCT01597908 · started 2012 · scored riskier than 63% of active trials completed
• A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma NCT01689519 · started 2013 · scored riskier than 83% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.